Clinical trials
Liver Cirrhosis, Alcoholic clinical trials
Below are recruiting liver cirrhosis, alcoholic clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06493799RecruitingPhase 3
Injectable placenta extract for fatty liver disease
This trial tests an injectable medication made from human placenta to see if it can improve liver health in people with fatty liver disease (from alcohol or other causes). It may help lower liver enzyme levels and reduce liver damage.
Yongin-siAges 19–70 - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT06764966RecruitingPhase 2
Statin and beta blocker study for liver disease
This trial tests if adding a statin to beta blocker treatment helps people with advanced liver disease (cirrhosis) who have had complications like fluid buildup, confusion, or bleeding. It is for patients who are already taking a non-selective beta blocker and will be followed for 12 months.
Charleston, West VirginiaAges 18 years+ - NCT06814990Recruiting
Heart and liver study for TIPSS patients
This study uses MRI and echocardiography to check heart function in people with alcohol-related liver cirrhosis who need a TIPSS procedure. It aims to learn more about how the heart works in these patients.
Jena, ThuringiaAges 18–99 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT04190849Recruiting
Children’s liver fat disease registry in Europe
This is a registry study collecting information about children and teens with fatty liver disease that isn’t caused by alcohol. It aims to better understand this condition and may help future research and treatments.
MaastrichtAges Up to 18 years - NCT04689152RecruitingPhase 3
Cell treatment via liver artery catheter for alcoholic cirrhosis
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
Bucheon-siAges 20–71 - NCT04690972Recruiting
Collection of blood and tissue samples for liver disease research
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
StrasbourgAges 18 years+ - NCT04932577RecruitingPhase 2/Phase 3
Fecal transplant to treat complications of liver cirrhosis
This trial studies whether transferring healthy gut bacteria (from a donor sample) can improve outcomes for people with liver cirrhosis who have worsening complications. It may help by changing the gut microbiome, which can influence inflammation and liver health.
AarhusAges 18–75 - NCT05093881Recruiting
Follow-up study for people treated for alcoholic liver scarring
This study checks on people who previously received Cellgram-LC for alcohol-related liver cirrhosis (liver scarring) in an earlier trial. It helps researchers learn long-term safety and outcomes after that treatment.
Bucheon-siAges Any age - NCT05205954Recruiting
Home hospital care for adults with advanced liver disease
This pilot study tests whether a “home hospital” program can safely care for people with advanced liver disease after they are admitted to the hospital. It may reduce time in the hospital while still treating serious complications like fluid buildup, breathing fluid, or confusion from liver disease.
Boston, MassachusettsAges 18 years+ - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
La Jolla, CaliforniaAges 18–75 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05895136RecruitingPhase 2
Albumin plus blood thinner for severe cirrhosis after hospital recovery
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
ClichyAges 18–80 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT06307964Recruiting
Gut bacteria in alcoholic hepatitis
This trial is looking at bacteria inside the liver of people with alcoholic hepatitis. It may help understand how these bacteria affect the disease and lead to better treatments.
LyonAges 18 years+ - NCT06819917Recruiting
Liver fibrosis test study for fatty liver disease
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
CopenhagenAges 18–75 - NCT06855056Recruiting
Studying new markers for recovery from liver cirrhosis complications
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
Clichy, FranceAges 18–80 - NCT06866496Recruiting
Better remission in alcohol-related liver cirrhosis
This trial tests if an optimized treatment plan can improve remission in people with liver cirrhosis caused by alcohol. It aims to help patients achieve better health outcomes.
Hvidovre, Capital RegionAges 18 years+ - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT07169526Recruiting
Health literacy and confidence in alcohol-related liver cirrhosis
This study looks at how well patients with alcohol-related liver cirrhosis understand health information and feel confident managing their health. It aims to find ways to support patients better.
HanoverAges 18–99 - NCT05699018Recruiting
Screening people with liver scarring in primary care
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
AngersAges 40–80 - NCT06840652Enrolling by invitation
Baclofen for alcohol withdrawal in liver disease
This trial tests if baclofen, a medicine for alcohol dependence, is safe and works for people with chronic liver disease who are actively drinking. It may help you stop drinking alcohol safely.
Sabadell, BarcelonaAges 18–75
Hear when a new Liver Cirrhosis, Alcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cirrhosis, alcoholic?
- Yes. Clin2 currently lists 95 recruiting liver cirrhosis, alcoholic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cirrhosis, alcoholic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cirrhosis, alcoholic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.